Evaluation of the efficacy and safety of original filgrastim (Neupogen (R)), biosimilar filgrastim (Leucostim (R)) and Lenograstim (Granocyte (R)) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors

摘要

Objectives and Aim: In this study, we aimed to compare the potency of different G-CSF agents including original filgrastim (Neupogen (R)), biosimilar filgrastim (Leucostim (R)) and Lenograstim (Granocyte (R)) on CD34(+) cell mobilization in patients that underwent allogeneic hematopoietic stem cell transplantation (alloHSCT).